| To: Cindy Powell who wrote (165) | 8/27/1998 1:15:00 AM | | From: Dr. Bob | | | |
Hello Cindy:
Just discovered two interviews which Lee Kulas and Dr. Novick recently gave which are very enlightening: check them out at: www.reutershealth.com and www.STNN.com (wall street reporter interview which can be heard in audio format).
Best!
Dr. Bob |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Dr. Bob who wrote (167) | 8/31/1998 2:04:00 PM | | From: Cindy Powell | | | |
Hello Dr. Bob and all,
Sorry it has taken me longer than promised to get back to the thread!
Thanks for the URL's and the info Dr. Bob :o)
As promised, here is the shareholders letter:
Dear Shareholders,
Please allow me a few moments of your time to update you on the activities, accomplishments and recent developments which your management team has undertaken during the last six months. First, let me ask your understanding in not releasing a "Shareholder letter" last quarter, as the last press releases demonstrate, we have been actively engaged in a variety of negotiations which required strict confidentiality. While we all appreciate the constant flow of information, I am sure you understand the absolute necessity of maintaining a tight level of confidentiality regarding our strategies, business development plans and eventual partnerships until we are certain that public disclosure will not compromise the Company's interests.
At this time, however, I would like to share with you the thoughts and strategic direction which went into the activites which have recently been disclosed. For your convenience, I have enclosed copies of these press releases for your reference. In addition, I encourage you to regularly review the company's SEC filings which may be accessed at either: "www.sec.gov.com"; or through the Company's website homepage: "www.MDI-P.com".
THE MDI MISSION STATEMENT
The management of Medical Discoveries Inc. is committed to transforming MDI into a revenue producing, "world class" Bio-Pharmaceutical Company. This means that while we continue in the development of our core compound, MDI-P, for eventual commercialization, we must, in the meantime, create more immediate revenue producing opportunities. We plan to achieve this objective by capitolizing on the ever-increasing business and market opportunities which our core electrolysis technology, patents, and research and development scientists have made available.
As a shareholder, it is important you realize that the activities we have undertaken, and those which we will continue to pursue, are part of a well-defined strategy to maximize the significant investment MDI has made to date in technology, patents, research, validation testing and employees. At the same time, however, we are continuing on a "regulatory approval timetable" with MDI-P targeted at HIV/AIDS (anti-viral), Candida Albicans (anti-fungal) and Vancomycin resistant strains of Enterococcus (anti-bacterial) therapeutic applications, and sterilization of medical products.
The decision to enter "consumer products" markets such as home water purification, wound repair and skin care, and "cosmeceuticals" enables MDI to quickly obtain revenues and establish our technologies in a leadership position, with no diversion from our pursuit of FDA approval of MDI-P.
SUMMARY OF PRESS RELEASES
(Please refer to press releases already made available.)
SHAREHOLDER VALUE PROGRAM
We have established a Shareholder Value Program which provides you the opportunity to take advantage of special pricing for products from MDI HealthCare Systems and Regenere. The attached Shareholder Value Business Reply Card offers special introductory pricing to shareholders on both the Millenium Aqua series products, and Kelo-cote. We are pleased to be able to provide our shareholders an opportunity to personally enjoy the benefits of these truly unique products.
Thankyou for your continued loyalty and support of our company. Until our next communication, I remain
Very Truly Yours,
Lee F. Kulas
President and Chief Executive Officer
|
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Zencone who wrote (169) | 10/29/1998 11:40:00 AM | | From: Jimmy Nicholson | | | |
Board is quiet? Just picked up the stock off the MOVERS list nice % gain so far today! Anybody have any ideas on why the jump? I am new to this stock just trying to get some info. b4 i jump in?
Thanks,
Jimmy |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Zencone who wrote (171) | 12/29/1998 1:32:00 PM | | From: Cindy Powell | | | |
Greetings all,
Medical Discoveries announcing a "Research Support Agreement" with the Dana-Farber Cancer Institute, "a major Teaching Affiliate of Harvard Medical School" is really great news!
And Harvard Professor Robert Finberg M.D. at the helm as principal investigator ain't too shabby either!
I hope everyone reads the news release in it's entirety and realizes the significance of MDI-P as being categorized as a "new" portal to the AIDS battle, with mechanisms that work differently than anti-retroviral mechanisms.
Go Medical Discoveries!
Cindy |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| To: Jimmy Nicholson who wrote (173) | 1/14/1999 4:07:00 PM | | From: Cindy Powell | | | |
News!
Medical Discoveries, Inc. Enters $3 Billion Scar Treatment Market
LAYTON, Utah, Jan. 14 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC - news) announced today that it's newly formed Consumer Products division, MDI HealthCare Systems, Inc., has launched the first in a series of scar management/skin care products, which are derived from its patented and proprietary electrolysis and other technologies. The company's flagship product, InvisiScar™ the invisible scar therapy™ treatment, is the first in a series of scar management/skin care products to be introduced by MDI HealthCare Systems, Inc.
''The launching of InvisiScar™ is part of a corporate strategy to maximize the innovative, proven technologies and intellectual property of our parent company, Medical Discoveries, Inc., by developing products targeted at profitable and growing consumer markets where we can make a significant contribution. The scar management/wound care market in the United States is estimated to be $3.5 billion, and growing, with 63 million new scars formed every year'', stated Lee F. Kulas, President and CEO, ''and MDI HealthCare Systems, Inc. intends to be a significant player in this exciting market.''
InvisiScar™ is a discreet, convenient, effective two-step therapy that combines two proven therapeutic agents to help soften, flatten and diminish unsightly scar tissue. Step One: Aqua Cleanse™ pretreatment pads are used to cleanse, hydrate and disinfect the skin and soften scar tissue. Step Two: InvisiScar™ offers the consumer all the benefits of ''gel sheeting'' without the difficulties associated with its application. InvisiScar™ is an invisible, odor-free, moisturizing topical gel that works discretely around-the-clock to soften, flatten, and reduce scar tissue to a more normal color and texture.
''The trend today is for the development of scar management and treatment alternatives which are easy to use, affordable, effective and safe,'' stated MDI HealthCare Systems, Inc., VP Research & Development, Jack Kushner. ''Based upon the science, research, testing and proprietary technologies used, InvisiScar™ is an effective and affordable treatment for skin trauma including cuts, burns, scars and cystic acne.''
The company has already signed major distribution agreements both in the United States and selected overseas markets. According to Neal G. Ofiesh, VP Sales, ''We are using a combination of corporate distribution agreements, independent distributors selling to the medical community, and direct consumer sales via nationwide advertising in selected women's magazines.''
Director of Operations, Troy Fullmer advised, ''We have been ramping up production during the last few weeks in accordance with distributor requirements, and are ahead of schedule for our national launch this month. Now our focus is transferring two products from development into manufacturing for launching in March and April.''
For further information about InvisiScar™ and the other scar management/skin care products provided by MDI HealthCare Systems, Inc., please direct all inquiries as follows: Distribution Availability: Neal G. Ofiesh, Vice President of Sales: (724-334-0500); Ordering Information: (1-877-343-6373) for all other Questions: Troy Fullmer, Director of Operations, (801-771-0523).
SOURCE: Medical Discoveries, Inc.
--------------------------------------------------------------------------------
|
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last ReadRead Replies (1) |
|
| To: Cindy Powell who wrote (174) | 2/23/1999 11:14:00 PM | | From: Zencone | | | |
Medical Discoveries, Inc. Announces Major
International Distribution Agreement for InvisiScar
Company Press Release
LAYTON, Utah, Feb. 23 /PRNewswire/ -- Medical Discoveries, Inc. (OTC Bulletin Board: MLSC - news) announced today
that its newly formed Consumer Products division, MDI HealthCare Systems, Inc., has signed an exclusive distribution
agreement with Fox Croft Trading Co., an international pharmaceutical trading company, to sell a minimum of 4,000 units of
InvisiScar(TM) a month exclusively in Brazil. This agreement represents a financial commitment of just under $1 million per
year. InvisiScar(TM) is a discreet, convenient, effective two-step therapy that combines two proven therapeutic agents to help
soften, flatten and diminish unsightly scar tissue.
''This agreement propels InvisiScar(TM) into the estimated $3.5 billion scar management/wound care market and marks a
significant financial and sales achievement for the Company since the launching of InvisiScar(TM) last month,'' stated Lee F.
Kulas, President and CEO. ''We are looking forward to a long and successful relationship with Fox Croft Trading Co., and
remain focused on the potential opportunities with Brazil and other international and domestic markets for our scar
management/skin care products.''
InvisiScar(TM) is a discreet, convenient, effective two-step therapy that combines two proven therapeutic agents to help
soften, flatten and diminish unsightly scar tissue. Step One: Aqua Cleanse(TM) pretreatment pads are used to cleanse, hydrate
and disinfect the skin and soften scar tissue. Step Two: InvisiScar(TM) offers the consumer all the benefits of ''gel sheeting''
without the difficulties associated with its application. InvisiScar(TM) is an invisible, odor-free, moisturizing topical gel that
works discretely around-the-clock to soften, flatten, and reduce scar tissue to a more normal color and texture.
For further information about InvisiScar(TM) and the other scar management/skin care products provided by MDI HealthCare
Systems, Inc., please direct all inquiries as follows: Distribution Availability: Neal G. Ofiesh, Vice President of Sales,
(724-334-0500); Ordering Information: (1-877-343-6373); for all other Questions: Troy Fullmer, Director of Operations,
(801-771-0523).
SOURCE: Medical Discoveries, Inc. |
| | MLSC Blood decontaminant recieves patent!!! | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
